Biologics: Role in rheumatoid arthritis

Thanusubramanian, Harish and Amberkar, Mohan Babu V and Kumari, Meena and Kishore, Kamal (2014) Biologics: Role in rheumatoid arthritis. World Journal of Pharmaceutical Research, 3 (7). pp. 746-754. ISSN 2277 – 7105

[img] PDF
rheumatoid arthritis.pdf - Published Version
Restricted to Registered users only

Download (349kB) | Request a copy


Rheumatoid arthritis is an autoimmune disease which is chronic in nature and the exact etiology is unknown. Genetic and environmentalfactors disrupt the immune system which causes interaction between the T-cells and antigen presenting cells (APC). Biologic diseasemodifying antirheumatic drugs (DMARDs) are biologic response modifiers that target a particular protein that contributes to rheumatoid arthritis (RA). Biological agents are anti-TNF agents, abatacept, rituximab, tofacitinib citrate, anakinra, tocilizumab and some under trial drugs. Various studies have shown that efficacy of biological DMARD+ conventional synthetic DMARD combination is more effective than only biological DMARD treatment. Various adverse effects are seen with biologics caused due to suppression of the immune system. Biologics are given according to 2013 EULAR (EUROPEAN LEAGUE AGAINST RHEUMATISM). The use of biologics is determined by measuring the disease activity with certain tools like Simplified Disease Activity index (SDAI) and Clinical Disease Activity Index (CDAI).

Item Type: Article
Uncontrolled Keywords: Anakinra; anti-TNF agents; CDAI, EULAR; infusion reaction; SDAI; tocilizumab.
Subjects: Medicine > KMC Manipal > Pharmacology
Depositing User: KMC Manipal
Date Deposited: 30 Sep 2014 10:47
Last Modified: 30 Sep 2014 10:47

Actions (login required)

View Item View Item